Flygenring J, Hansen J, Holst B, Petersen E, Sørensen A
Acta Psychiatr Scand. 1984 May;69(5):398-408. doi: 10.1111/j.1600-0447.1984.tb02511.x.
Seventy-two hospitalized patients with alcohol withdrawal symptoms were treated with either carbamazepine (Tegretol) or barbital ( Diemal ) in a randomized, double-blind trial. The dose of trial medication as well as the duration of treatment was individual, corresponding to the conventional treatment schedule. During the trial period daily records were kept of target withdrawal symptoms, global evaluation, the patient's subjective feeling and unwanted effects. Sixty patients completed the treatment successfully. The two treatment groups were homogeneous as regards patient characteristics, pre-treatment disease severity and drop-out rate. No statistically significant differences were found in efficacy between the two treatments, and both drugs were well tolerated. It is concluded that carbamazepine is a valuable alternative drug in the treatment of mild and moderate alcohol withdrawal symptoms.
在一项随机双盲试验中,对72名有酒精戒断症状的住院患者使用卡马西平(得理多)或巴比妥(狄俄玛)进行治疗。试验药物的剂量和治疗持续时间因人而异,与传统治疗方案一致。在试验期间,每天记录目标戒断症状、总体评估、患者的主观感受和不良反应。60名患者成功完成治疗。两个治疗组在患者特征、治疗前疾病严重程度和退出率方面具有同质性。两种治疗方法在疗效上没有发现统计学上的显著差异,且两种药物耐受性良好。得出的结论是,卡马西平是治疗轻中度酒精戒断症状的一种有价值的替代药物。